Skip to Content

Posts tagged with "Cancer"

  • Business and Markets

    Merck Does Something. Or Not. Maybe Something Else Instead.

    There’s some Merck news today, via FiercePharma. First off, their R&D head Roger Perlmutter sat down with some of the most prominent analysts for a chat about the company’s direction – and they came out with two completely different stories. Big changes? Minor ones? I wonder if people were taking away what they wanted to… Read More
  • Cancer

    How Goes the War?

    There’s an article at The Atlantic titled “More Money Won’t Win the War on Cancer”. I agree with the title, although it’s worth remembering that lack of money will certainly lose it. Money, in basic research, is very much in the “necessary but not sufficient” category. The article itself is making the case… Read More
  • Business and Markets

    Amgen Buys Onyx

    So Amgen’s bid for Onyx look like it’s going through, and the reaction of John Carroll at FiercePharma was to tweet “Expect big layoffs soon”. He took some flak for being such a downer, but he’s right, as far as I can see. Amgen isn’t buying Onyx for their research staff, or any of their… Read More
  • Cancer

    Aileron Reports Some Stapled Peptide Results

    Here’s a publication from Aileron Therapeutics on their stapled-peptide efforts against MDM2/p53 for cancer. (I wrote about that target here, so you can check out the links in that post for background). This compound (ATSP-7041) goes after both MDM2 and MDMX, activating the suppressed p53 pathway, and it seems to do a good job of… Read More
  • Biological News

    Another T-Cell Advance Against Cancer

    The technique of using engineered T cells against cancerous cells may be about to explode ever more than it has already. One of the hardest parts of getting this process scaled up has been the need to extract each patient’s own T cells and reprogram them. But in a new report in Nature Biotechnology, a… Read More
  • Cancer

    Cancer and Autism: Slow Down

    The New York Times had a rather confusing story the other day about the PTEN gene, autism, and cancer. Unfortunately, it turned into a good example of how not to explain a subject like this, and it missed out (or waited too long) to explain a number of key concepts. Things like “one gene can… Read More
  • Cancer

    Kevan Shokat At The Challenges in Chemical Biology Conference

    Kevan Shokat is now talking about his lab’s work on using Drosophila models for kinase inhibitor discovery in oncology. I always like hearing about this sort of thing; very small living models have a lot of appeal for drug discovery. You’d think that screening in fruit flies would be problematic for understanding human efficacy, but… Read More
  • Cancer

    Stuart Schreiber at the Challenges in Chemical Biology Conference

    I’m listening to Stuart Schreiber make his case for diversity-oriented synthesis (DOS) as a way to interrogate biochemistry. I’ve written about this idea a number of times here, but I’m always glad to hear the pitch right from the source. Schreiber’s team has about 100,000 compounds from DOS now, all of which are searchable… Read More
  • Cancer

    More Details on T-Cell Leukemia Therapy

    There’s an excellent overview at Science of the work of David Porter and Carl June at the University of Pennsylvania on T-cell-based cancer therapy. It turns out that when the dramatic reports came out on their first three patients, the team was out of funding and trying to see if they could get someone interested. Read More
  • Cancer

    A Specific Crowdfunding Example

    I mentioned Microryza in that last post. Here’s Prof. Michael Pirrung, at UC Riverside, with an appeal there to fund the resynthesis of a compound for NCI testing against renal cell carcinoma. It will provide an experienced post-doc’s labor for a month to prepare an interesting natural-product-derived proteasome inhibitor that the NCI w… Read More
...181920...